vinit6675's blog

Market Research Future (MRFR) announces the publication of its research report – Global Fetal Macrosomia Market 2017-2023

Considering the scenario of America’s fetal macrosomia market, this region is the largest in global fetal macrosomia market. Increasing adoption of technologically advanced diagnostic devices is the major driver for this market.

The Americas market is top revenue generating region in global fetal macrosomia market. This market mainly comprises of two regions, North America and Latin America. Due to availability of advanced diagnostic and treatment facilities, US is dominating country in this market.

Increasing awareness about fetal macrosomia and related medical complications are major factor for the growth of the market. North America is a very important region not only in America but also in global fetal macrosomia market. US is home for many top global players which are leading to research, new product development and revenue generation. This companies are funding and collaborating with independent laboratories and academic institutions for research that leading to innovation as well as new product development. Rapid adoption healthcare trends or practices are driving the growth for this market.

South America fetal macrosomia market is also growing significantly. The demand from emerging economies like Brazil is a major factor for market growth. Increasing awareness of fetal macrosomia, and rising healthcare expenditure are driving the growth for South America fetal macrosomia market.

However, some other factors are prohibiting the growth of the America’s market, especially in South America like, less knowledge of the prevention and treatments, traditional healthcare practices etc.

The American fetal macrosomia market has been segmented on the basis of diagnosis which comprise of ultrasound, antenatal testing, and others. Ultrasound is further sub-segmented into standard ultrasound, transvaginal scan, fetal echocardiography, 3-d ultrasound, dynamic 3-d ultrasound, and others. Antenatal testing is further sub-segmented into blood and urine tests, amniocentesis, chorionic villus sampling, and others. On the basis of treatments, the market has been segmented into medical care, surgical care, and others. Surgical Care is sub-segmented into cesarean delivery, and others. On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others

Major players currently present in the global Fetal macrosomia market include Carestream Health, Inc. (US),  Esaote SpA (Italy),  Fonar Corporation (US),  Fujifilm Holdings Corporation (Japan),  GE Healthcare (UK),  Hitachi Medical Corporation (Japan),  Hologic, Inc. (US),  Philips Healthcare (Netherlands),  Samsung Medison Co. Ltd (Republic of Korea),  Shimadzu Corporation (Japan),  Siemens Healthcare (Germany),  Toshiba Corporation (Japan),) and others.


Market Highlights

The global varicocele treatment market has been evaluated as a moderately growing market and it is expected to continue growing in the near future. Varicocele is an enlargement of the veins within the scrotum, the scrotum is a skin-covered loose bag that holds testicles. Increasing number of varicocele, availability of effective treatments, and increasing awareness are leading the growth for the market. The other. Advanced diagnostics and treatment are key factors for the market growth. The increasing demand from emerging economies of Asia are driving the growth for the market. Hospitals, researchers and academic institutes are continuously doing research to derive effective cure for varicocele that is another important factor for the growth of global varicocele treatment market.

The market for varicocele treatment was around USD 405.3 million in 2016 and is expected to reach USD 617.5 million by 2023 which is a projected CAGR of 6.2%.

Taste the market data and market information presented through more than 54 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Varicocele Treatment Market Research Report–Global Forecast to 2023.”

Major players in Varicocele treatment market:

There are plenty of large and small market players which operate in this market: Bayer (Germany), Depomed, Inc. (US), GlaxoSmithKline plc. (UK), INSYS THERAPEUTICS, INC. (US), Janssen Global Services, LLC (Belgium) Mylan N.V. (US), Novartis AG (Switzerland), PurduePharma (US), Pfizer Inc. (US), and others.

Regional Analysis:

Considering the global scenario of the varicocele treatment market, there are four main regions- America, Europe, Asia Pacific, and Middle East & Africa. The Americas are holding largest market share. The Americas mainly include North America and Latin America. North America is largest and top revenue generator market for varicocele treatment. Europe is second largest market. Germany, UK, and France are the major markets while Eastern European varicocele treatment market is also growing. Asia Pacific varicocele treatment is also growing significantly. Some major factors like increasing awareness of the disease, developing healthcare sector, and rising healthcare expenditure are driving the growth for Asia Pacific varicocele treatment market. Middle East & Africa varicocele treatment market is expected to have limited growth mainly due to lack of knowledge of the disorder, and limited access to the healthcare facilities. Due to developed healthcare infrastructure and high expenditure on healthcare, Middle East is dominating region as compared to Africa.


Global Varicocele treatment market has been segmented on the basis of grade which comprise grade I, grade II, grade III, and others.

On the basis of diagnosis it is segmented into physical exam, imaging test, and others. Imaging test further sub-segmented into thermography, scrotal ultrasound, and others

On the basis of treatments, the market has been segmented into varicocele repair, varicocele embolization, medication, and others. Varicocele repair is sub-segmented into open surgery, laparoscopic surgery, percutaneous embolization, and others. Medication is sub-segmented into painkillers, and others. Painkillers includes acetaminophen, ibuprofen, and others.

On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.



A hemangioma can be described as the birthmark or benign tumors of infancy that happens with the abnormal collection of blood vessels. Globally, around 5% to 10% of infant suffer from this disease. The global hemangioma market can witness a moderate growth marking 3.2% CAGR between 2018 and 2023, which the report of Market Research Future (MRFR) confirms as the forecast period.

The process would witness a rise to USD 294.8 million during the same period. Hemangioma diagnosis and treatment are not cumbersome procedures. This does not require any major tests for detection and often it disappears without the application of any major medicines. However, if the disease causes any trouble in the vision or affects other systems in the body then medication and laser surgery are the way out. The treatment may find usages of drugs like Beta-blocker and Corticosteroid medications.

Growth in the number of cases getting registered each day across the world and the advent of better treatment opportunities are things that can influence a strong growth rate in the coming years. The market is also expected to create significant progress with increasing inclusion of treatments and using drug therapies. Such wide-scale use of the latest technologies can make sure that the market gains proper growth.


The global market report covering the hemangioma can be segmented by type, diagnosis, and treatment. Such an in-depth analysis would provide ample growth opportunities for the market.

By type, the hemangioma market report would include cavernous hemangioma, capillary hemangioma, Lobular capillary hemangioma (pyogenic granuloma), compound hemangioma, and others. The cavernous hemangioma segment can be segmented into liver cavernous hemangioma, cerebral cavernous malformations, and eye cavernous hemangioma.

By diagnosis, the market report on the hemangioma market can be segmented into a CT scan, MRI, ultrasound, and others.

By treatment, the hemangioma market can be segmented into surgery, laser therapy, medical therapy, and others. The medical therapy segment can be segmented into intralesional, systemic, and topical. The laser therapy segment can be segmented into an intralesional laser, Flash lamp pulsed dye laser, and carbon dioxide laser.

Competitive Landscape: 

MRFR has collected information regarding the global market for hemangioma. The process has included recent moves taken by companies that can impact the market. These companies are Pierre Fabre (US), AstraZeneca (UK), Novartis AG (Switzerland), krimax Pharmaceuticals, and LLC. (US), Cutting Edge Laser Technologies (US), Pfizer Inc. (US), Quanta System S.p.A. (Italy), Linline Medical Systems (France), and others.

Physicians are considering Propranolol as the gold standard for infantile hemangiomas. The systematic use of propranolol can assist in providing a proper window for treatment.


Adenomyosis is defined as a medical condition in which the inner lining of the uterus (also known as the endometrium) breaks through the muscle wall of the uterus (the myometrium). The treatment of this medical problem is called adenomyosis treatment. A new report on the global adenomyosis treatment market, published by Market Research Future (MRFR), states that this market can visualize progress at 4.1% CAGR during the forecast period (2018-2023). In terms of value, the market can be worth USD 291.5 Mn by the end of the forecast period.

The biggest driver for the global adenomyosis treatment market growth is the global prevalence of adenomyosis. The increasing awareness about adenomyosis as well as its treatment is boosting the global adenomyosis treatment market by creating the demand, supply, and sales for new drugs and therapies, along with advanced medical technology-focused towards the adenomyosis. Hence, new opportunities are arising for market growth. During the forecast period, increased funding for research & development (R&D) to develop more advanced products (medical devices) is expected to reflect favorably on the market. However, the market in developing countries can face hurdles as many people are not aware of this medical problem.

Market Segmentation

The global adenomyosis treatment market segmentation encompasses diagnosis, type, and treatment. MRFR’s take on the market marks various facets of the market in-depth.

The diagnosis-based segmentation of this market covers endometrial biopsy, magnetic resonance imaging (MRI), ultrasound, and others. The ultrasound segment has been sub-segmented into transabdominal ultrasound and endovaginal ultrasound which is also known as transvaginal ultrasound.

By type, the market includes adenomyoma, diffuse, focal, and others.

By treatment, the market covers anti-inflammatory drugs, hormone medications, and hysterectomy. The anti-inflammatory drugs segment has been sub-segmented into Advil, ibuprofen, Motrin ibuprofen (Motrin IB), and others.

The hormone medications segment has been sub-segmented into aromatase inhibitors and Gonadotropin-releasing hormone (GnRH) agonists. The hysterectomy segment radical hysterectomy, supracervical hysterectomy (also known as a subtotal hysterectomy), and total hysterectomy.  

Regional Segmentation

A geographical outlining of the global adenomyosis treatment market covers the Americas (North America & South America), Asia Pacific, Europe, and the Middle East & Africa (MEA).

The Americas is the biggest regional market as North America alone has the potential of becoming a powerful regional market. Due to the advanced medical facilities being available in the USA North America is a larger regional market segment compared to South America. North America is the largest regional market segment due to the rapid adoption of new drugs and therapies. Continuous innovation on the technological front and heavy use of technology in the medical sector boost market in this region. USA and Canada are generating the maximum revenue in this region.

Europe is the second-largest regional market as many important market players are based in Europe. Due to the reasons the same as in The Americas, Western Europe is a bigger market compared to Eastern Europe. The major market share comes from France, Germany, Spain, Italy, and the UK.

The Asia Pacific region is an important regional market due to improving medical sector and stable technological progress. In this report, this regional market has been segmented into Asia and the Pacific. In Asia, the key country-specific markets are China, India, Japan, and South Korea. An observation of the remaining countries in Asia and the Pacific region featured in this report calculates the additional market revenue from some other countries.

In the MEA region, the market has been slow due to limited availability of advanced medical facilities. Countries focused in the report include Egypt, Saudi Arabia, and the UAE.

Key Players

Big players in the global adenomyosis treatment market are Bayer AG (Germany), Ferring B.V. (Switzerland), Johnson & Johnson Consumer Inc. (USA), Merck KGaA (Germany), Novartis (Switzerland), Pfizer Inc. (USA) and Speciality European Pharma (UK).


Market Insight

Veterinary surgical equipment market 2020 is all set to touch USD 2760.6 million by 2023, claims Market Research Future (MRFR). The market’s growth is anticipated to be at a rate of 6.3% from 2017 to 2023 (evaluation period). We will provide COVID-19 impact analysis with the report, along with all the extensive key developments in the market post the coronavirus disease outbreak.

Primary Drivers and Barriers

The spike in surgeries among pets in emerging countries in recent years has led to significant market growth across the world. Some of the most common surgical procedures among pets include cataract, dental, spay or neuter, wound repair and hip dysplasia. The market growth has also been the outcome of the dramatic surge in the number of practitioners worldwide and the high frequency of technological innovations with regard to these instruments. Some other factors promoting market growth include the accelerated demand for health insurance of animals, rising adoption of companion animals and surge in government initiatives against zoonotic diseases.

The growing cases of periodontal issues in pets combined with the escalating demand for better quality treatment options has also driven the demand for veterinary surgeries and in turn, the need for advanced veterinary surgical instruments. In short, the fast growth in the demand for advanced oral surgeries and periodontal surgeries has led the market to greater heights in the past few years. Rising availability of effective post-operative pain management treatment options has also caused significant hike in surgical intervention, subsequently fostering the demand for veterinary surgical instruments.

Health conditions with regard to obesity among animals have risen in recent times, including heart diseases, osteoarthritis, diabetes and dental problems. Most of these require surgeries, which translates into higher demand for effective surgical instruments. Noteworthy breakthroughs in the veterinary field and surgical instruments like in prosthetics and orthotics along with microfracture detection technology in racehorses has benefitted the market to a large extent. In addition, the increasing uptake of simulation models for orthopedic surgeries has bolstered the demand for surgeries for the mentioned conditions. A majority of the renowned vendors are highly focused on taking up strategies such as acquisitions, mergers, partnerships, agreements and new product launches to enhance their revenue share, which ultimately induces market growth as well.

To illustrate, in June 2020, Docsinnovent Ltd launched v-gel supraglottic airway devices for rabbits and cats. The device was originally launched in 2012, and since then, it has been made more compact so as to allow more space in the mouth for the dentist. These devices seal better; are single-use and help enhance hygiene standards.

Segmental Insight

Type, application and animal are the top segments based on which the market has been categorized in the MRFR report.

The veterinary surgical instruments industry, depending on types, can be considered for forceps, scalpel handles, scissors, dressing, retractors and needle holders. The market for scissors has remained dominant since 2016, with the needle holders market coming in second.

Some of the top applications covered in the study include sterilization, orthopedic, dental and ophthalmic. Dental application is the largest in the market, trailed by the ophthalmic segment.

Animal-based segments in the global market include felines, large animals as well as canines.

Regional Study

Key markets for veterinary surgical instruments across the world include Asia Pacific/APAC, Middle East and Africa/MEA and North America along with Europe.

The US, one of the most developed countries in North America, is the world leader, as a result of the supportive reimbursement scenario along with the presence of a well-organized dairy and meat industry. The increasing efforts taken by the renowned firms to upgrade their product range, while ensuing top-quality standards helps foster the growth of the veterinary surgical instruments market in the region. The surge in pet insurance has also been favorable for the regional market in recent years. Reports by North American Pet Health Insurance Association reveal that over 2.5 million pets in Canada and US had insurance as of 2018.

The second lead has been procured by the European market, while South American countries like Paraguay, Uruguay and Argentina are also observing significant growth in the global market. Rising chronic disorder cases among animals have boosted surgical intervention and motivated the market growth in these areas.

However, the most promising market for veterinary surgical instruments is APAC, with China and India emerging as the leaders. Growth in pet humanization combined with the mounting awareness with regard to animal welfare can be cited as the top contributing factors to the market growth in Asia Pacific. Japan is one of the fast advancing markets in the region, since the country observes high adoption rate of modern techniques like new diagnostic services along with surging geriatric pet populace.

Key Industry Firms

Some of the key industry firms studied in the MRFR study include Sklar Instruments, Surgical Holdings, Medtronics, B.Braun, Jørgen KRUUSE A/S, Eickemeyer Veterinary Equipment Inc., Whittemore Enterprises, Inc., and more.


Obesity management is a set of programs designed to lose weight without causing harm to an individual. Development of new approaches due to sedentary lifestyles led by adults and negative effects of fads have brought to the fore the need to reduce obesity. The global obesity management market report compiled by Market Research Future (MRFR) contains insights, hurdles, measures, and other dynamic factors for the period of 2019 to 2025 (forecast period). The COVID-19 pandemic and its effect on the market has been noted.

Market Scope

The global obesity management market is poised to inflate to a valuation of USD 9.34 billion by 2025. It can exhibit a CAGR of 8.4% over the forecast period.

The lifestyle of convenience, consumption of snacks, large number of obese individuals, and availability of obesity treatment methods are major drivers of the market. According to a study in 2016, out of 2 billion overweight individuals, close to 650 million were found to be obese. The risk of being diagnosed with cardiovascular disease and diabetes due to obesity can provide plenty of growth opportunities to the global obesity management market.

Awareness of obesity management, presence of various healthy diets, option of bariatric surgery, and prevalence of lifestyle diseases can drive the market growth over the forecast period. Public health intervention campaigns endorsed by governments are likely to facilitate in market growth. Furthermore, the presence of nutrition experts and establishment of fitness centers can boost the global obesity management market.

The COVID-19 pandemic has created a massive opportunity for the market owing to people adhering to sedentary lifestyle and ordering in foods. Obesity management can reduce the susceptibility ratio of patients attaining the virus and further the market growth.


The global market for obesity management, by type, is divided into medication and surgery. Moreover, the medication segment is further classified into liraglutide, orlistat, lorcaserin, bupropion and naltrexone, and phentermine and topiramate. Furthermore, the surgery is sub-segmented into laparoscopic adjustable gastric band, gastric sleeve, and gastric bypass.

Regional Analysis

The Americas dominated the obesity management market owing to the increasing awareness among the masses, the increasing prevalence of obesity, surgical options, weight management medicines, and the growing adoption of advanced technology. According to the Centers for Disease Control and Prevention (CDC), obesity is a major concern in the region and approximately 93.3 million adults were diagnosed with obesity in 2016. The self-isolation during the COVID-19 pandemic is driving people to consume processed foods and increases the risk of metabolic disease. Obesity management programs can help in curbing the obesity pandemic and boost the market growth in the process.

In 2018, Europe accounted for the second-largest share of the market. This can be attributed to the high expendable income levels of consumers and consumption of restaurant food. A new slew of measures by the National Health Services, a government aided healthcare service, is likely to curb obesity with the help of obesity management strategies. This is propagated by ban on Ads promoting sugar drinks, unhealthy foods, and mandates for alcoholic drinks to be displayed with hidden calorific values on menus.

However, the APAC region is expected to grow at the fastest rate in obesity management throughout the forecast period due to rising participation of market players and a large geriatric population.

On the other hand, the MEA obesity management market holds the least share due to the low economic development in Africa.

Competitive Outlook

F. Hoffmann-La Roche Ltd, AstraZeneca, Merck Sharp & Dohme Corp., Apollo Endosurgery, GlaxoSmithKline plc., Herbalife Ltd., Pfizer Inc., and Ethicon, Inc. are notable players of the global obesity management market.


Market Research Future (MRFR) has identified the key trends and patterns governing the global conjunctivitis market in a detailed report. The conjunctivitis drugs market is pegged to reach USD 1.08 Bn at a CAGR of 3.1% over the forecast period of 2016-2022.

Growing awareness about the treatment options available for conjunctivitis due to initiatives taken by healthcare organizations to spread awareness about the contagious disease is boosting the conjunctivitis market. Moreover, the increased focus of healthcare sector on eye care has reflected positively on the growth of the market.

Poor hygienic conditions in developing and underdeveloped countries in combination with a low level of awareness among has raised the occurrence of conjunctivitis. Additionally, huge unmet medical needs and rise in disposable income in developing countries has induced high demand within the conjunctivitis drugs market.

Currently, no drug is available in the market which can treat viral conjunctivitis. However, hefty investments from pharmaceutical companies and a robust pipeline with numerous drugs in the development stage are likely to provide ample growth opportunities to the conjunctivitis drugs market. Moreover, against the backdrop of towering demand for efficient treatment options for viral conjunctivitis drugs, massive investments are being made on R&D activities which are set to push the market further. The US FDA has been approving a lot of drugs in recent times which is expected to augment the market growth over the forecast period.

Contrarily, the growth of the market might be undermined by diagnosis rate which is considerably low for conjunctivitis given the self-limiting nature of the disease. Loss of various patent blockbuster drugs such as Besivance, Vigamox, Zymaxid, and Moxeza have impacted the market growth adversely.

Industry Updates

March 2019 - Aldeyra Therapeutics, a biotechnology company focused on the development of immune-mediated ocular and systemic diseases, announced that positive results its Phase III ALLEVIATE trial of reproxalap for the treatment of allergic conjunctivitis. This confirms reproxalap as a potential and clinically meaningful approach for the treatment of conjunctivitis. The new drug is due for FDA and NDA (New Drug Application) approval.

March 2019 - Alembic Pharmaceuticals, a pharmaceutical company headquartered in India, announced that it had received FDA approval for its new product, zelastine Hydrochloride Ophthalmic Solution, aimed at the treatment of allergic conjunctivitis.

Competitive Landscape

Allergan Plc, Valeant Pharmaceuticals, Pfizer Inc., Merck & Co. Inc., Actavis Plc., Akorn Pharmaceuticals, Bausch & Lomb, and Alcon/ Novartis AG are the distinguished players in the global conjunctivitis market.


Global Anemia Drugs Market - Overview

Growing awareness and increased investment & interest towards developing drugs to combat this condition are contributing favorably to growth of the market. Since anemia significantly affects the quality of life and has also has been found as a causative factor for reducing the survival rates in cancer related cases.

Since anemia is more prevalent in women than in men, the market is majorly driven by them. Increasing rates of anemia diagnosis in pregnant women and deficiency of iron intake in diets and low levels of iron absorption level are causing expansion of the anemia drug market. Certain types of anemia types will be responsible for shaping the anemia drug industry in the forecast period.

According to a report published by Market Research Future on Global Anemia Drugs Market Research Report- Forecast to 2022 states that the global market for Anemia Drugs is worth US$21.4 billion and will grow at an estimated CAGR of 8.4% to reach US$34.7 billion at the end of forecast period by 2022.The global market for anemia drugs is demonstrating a good trend of positive growth.

Global Anemia Drugs Market – Competitive Analysis

With the entry of industry players in the anemia drug segment, a trend of solid, volume-driven growth has been observed in the market with the introduction of various types of drugs for different uses. With companies aiming to capture a considerable share of the market segment as early as possible, they are competing and experimenting with various advantage points. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in the optimal strategies.

Some of the key players in this market are Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc. Some of the other prominent players are Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company and others.

Latest Industry News:

April 2017 Akebia Therapeutics, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that they have expanded their collaboration for vadadustat by entering into a collaboration and license agreement for Europe, China and other territories. Under the terms of this collaboration agreement, Akebia will receive $208 million or more in committed capital from Otsuka, including $73 million upon signing and $135 million or more of development funding. The companies are equally sharing the costs of developing and commercializing vadadustat in the U.S., as well as the profits from potential future sales of vadadustat in the billion dollar worth renal anemia market.

Jan 2017 A first-in-class drug for anemia caused by chronic kidney disease (CKD) has been developed by FibroGen and AstraZeneca which has cleared two phase III studies in China and will be filed for approval before the end of 2017.

October 2017 Amgen Inc. has entered in an agreement to buy Kirin-Amgen, its joint venture with Japan-based Kirin Holdings Co., for $780 million. Amgen and Kyowa Hakko Kirin, the biopharmaceutical arm of Kirin, formed the 50-50 partnership in 1984 to develop Epogen, a drug used to promote the growth of red blood cells in patients with anemia.


Snoring Control Device Global Market – Overview

The Global Snoring Control Device Market is growing with the rapid pace; mainly due the burgeoning Healthcare Sector, prevalence of snoring disorder and increasing need of effective measures to control the snoring disorders. According to a recent study report published by the Market Research Future, The global Snoring Control Device Market is booming and expected to gain prominence over the forecasted period.  The Market is estimated to demonstrate a huge growth by 2022, surpassing its previous growth records in terms of value & volume. The global Snoring Control Device Market is expected to reach USD 1,456 million in 2022 from USD 755 million in 2016. It has been noted that market is growing at steady pace and is expected to grow at the CAGR of 9.7% during the forecasted period 2016 – 2022.

The Global Snoring Control Device Market is predominantly driven by the rising awareness towards the impacts of snoring and the phenomenal results offered by Snoring Control Device and medications combined with rising number of geriatric population and obese populace. Additionally, technological advancements transpired in to the healthcare sector resulting in to affordable Snoring Control Device and treatments available for all is providing impetus to the market growth. Moreover, rising per capita income across the globe which is increasing the affordability and purchasing power of consumers is fostering the market growth up to large extent.

At the same time, scepticism of consumers towards the efficacy of the Snoring Control Devices due to which sometimes they consider the cost of these devices are unjustified is a major restraining  factor to the market growth.  Adversely, favourable regulatory framework in developed countries which support the development of medical devices to improve their efficiency is fostering the market growth.


Snoring Control Device Global Market – Segments

The Snoring Control Device market can be segmented in to 3 key dynamics for the convenience of the report and enhanced understanding;

Segmentation By Type  : Comprises Nasal Device, Oral Appliances, Chin Straps, Position Control Device, Tongue-Stabilizing Device, Expiratory Positive Airway Pressure Therapy Device (EPAP) and other.

Segmentation By Treatment:Comprises Injection Snoreplasty, Laser-Assisted Uvulopalatoplasty, Radiofrequency Ablation, Injection Snoreplasty, Palatal Stiffening and other.

Segmentation By Region                : Comprises Geographical regions - North America,                                                  Europe, APAC and Rest of the World.

Nasal Device has the largest market share in global Snoring Control device by types and the growth will be constant in future starting from 2016 till 2022.

The Oral Appliances segment will also play a major role in the growth of the Global Snoring control device market by types.

Snoring Control Device Market – Regional Analysis

The market is categorized and analyzed on the basis of geographical segmentation which includes Americas, Europe, Asia-Pacific, Middle East & Africa. Amongst all, North America has the largest market in the global Snoring control device market. North America holds approximately 36% market share for the global Snoring control device market, this is mainly because of the financial support from the government for research and development and support from regulatory framework which encourages related companies to develop new technologies in the following region.

Moreover in North America snoring control device treatment is growing rapidly due to increasing demand for the treatment of snoring disorder and companies which are more focused in to developing new technologies for the advancement of snoring control globally.

Europe is the second-largest market for Snoring Control Device. Asia Pacific is expected to be fastest growing market for snoring control device which is expected to grow at a stable CAGR for the forecasted year from 2016 to 2022.


Market Scope

Market Research Future (MRFR) asserts that the in-vitro diagnostics market can achieve a growth rate of 8.16% from 2020 to 2027. The market size should also surpass USD 102,500 Mn by the review period’s end.

Primary Boosters and Deterrents

Soaring awareness among patients regarding personalized medicines has raised the demand for in vitro diagnostics technology in recent years. Diagnostic tests, particularly those that offer real-time or rapid results have become a critical aspect of treatment regimens with respect to chronic conditions and diseases. Diagnostics tests help physicians reach an informed medical decision, which helps reduce the likelihood of adverse health events. A few of the most commonly deployed personalized treatments are therapeutic drug monitoring tests to decide drugs to treat HIV strains; cholesterol (and other lipid) testing to monitor the effectiveness of lipid lowering therapy; HbA1c tests (glycated hemoglobin) for monitoring diabetes; and so on.

The in vitro diagnostics industry is also gaining momentum on the back of surging use of fully automated instruments across several diagnostic laboratories. Compared to the traditional semi-automated tools and instruments, automated instruments are exhibit significant performance levels, are far more scalable, reduce the hands-on period of the technologists, deliver quicker results and also eliminate batch testing. In view of these advantages and the resultant increase in demand, firms are focused on designing automated instruments. Dearth in lab personnel along with the escalating test volumes that require more number of tests also drive the demand for laboratory automation in the global market.

Segmental Analysis

With respect to product & services, the market caters to instruments, data management software and reagents & kits. In the year 2017, the reagents and kits segment took the lead with the highest share in the global market and can continue to dominate with a growth rate of 9.34% over the review period.

Technology-wise, the key segments are clinical chemistry, immunoassay/ immunochemistry, microbiology, hematology and molecular diagnostics. Clinical chemistry segment owns over one-third of the total share in the global market, considering the increasing use of modern technologies in the clinical diagnostics field. The molecular diagnostics segment can however, project the fastest growth in the years ahead.

Major applications are non-infectious and infectious diseases. Since 2017, the infectious diseases segment has stayed at the top spot with the highest share of more than 60% in the global industry.

Top market end users are laboratories, academic institutes, and hospitals. Hospitals segment remains in the lead owing to the huge number of tests that are conducted in hospital settings.

Regional Status

The in-vitro diagnostics market’s geographical distribution comprises Europe, South America, the Middle East & Africa (MEA), North America, along with Asia Pacific (APAC).

In 2017, North America and South America together formed a share of nearly 40% in the global market. The North American market, in particular, can expect to stay highly profitable throughout the evaluation period. Additionally, the Asia Pacific market is more than likely to attain the highest growth rate over the forecast timeframe.

The North American market has been gaining at a stunning rate, mainly due to the escalating cases of infectious and chronic diseases in the United States and the rapidly growing elderly population. The soaring preference for effective point-of-care testing as well as personalized medicine, presence of Affordable Care Act (ACA) and the rising use of automated instruments also strengthen the market position in the region. The expanding application scope of molecular diagnostics along with increasing range of condition-specific tests and markers with innovations in proteomics and genomics could create lucrative opportunities for the regional market. Surge in FDA approvals encourage players to focus more on new launches, which in turns, aids in market growth.

The Asia Pacific market can procure the fastest growth rate in the years to come, backed significantly by rapidly emerging economies like India and China. Improving healthcare infrastructure and the escalating number of people opting for early diagnosis in view of mounting awareness levels coupled with the growth in the prevalence of chronic ailments also benefit the APAC market.

Top Firms

Bio-Rad Laboratories Inc., Sysmex Corporation, bioMérieux S.A, DiaSorin S.p.A, Ortho Clinical Diagnostics, Abbott Laboratories, Siemens AG, Grifols S.A, Becton Dickinson and Company, Danaher Corporation, Hoffmann-La Roche AG, and Thermo Fisher Scientific, Qiagen N.V. are some of the top manufacturers of in-vitro diagnostics worldwide.

Latest News

February 2021

TMRW Life Sciences has introduced the world's first ever automated cryo specimen management solution for eggs and embryos that are part of vitro fertilization. The TMRW platforms latest software-based management of millions of eggs s well as embryos will facilitate a smoother IVF procedure. The solution renders an unprecedented degree of safety at each phase of managing embryos and eggs as it accurately identifies every sample using radio frequency identification tracking, and also continuously monitors via TMRW's HIPAA-compliant, data-encrypted software.


Pages: 1 2 3 4 5 ... » »»